HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.
Pharma industry weight behind making daily oral contraceptives available OTC in the US gains substantial heft with Perrigo Company PLC’s planned acquisition of French firm HRA Pharma, which recently received UK approval for nonprescription sales of a daily-use progestin-only contraceptive.
With its acquisition of HRA, officially identified in France as Héra SAS, for €1.8bn ($2.1bn) in a cash deal announced...
A healthy diversity of different types of players and plenty of space for scaling up are among the reasons that investors remain interested in the consumer health sector, according to investment bankers speaking at the recent AESGP Annual Meeting.
Consumer health player PharmaSGP will be taken private by its biggest shareholder, FUTRUE.
Private equity firms now in control of Alliance Pharma weighing úp plan to offload Rx business to help finance strategy to drive up sales and growth.
Deal totaling as much as $880m extends C&D into additional product category with a brand it says is the fastest growing in the US hand sanitizer category and No. 2 brand in the category overall.
A round-up of the latest consumer health industry appointments: Kloserfrau makes changes to management in Germany; Haleon hires Pakistan head; Opella names Americas leader.
While sales of seasonal products struggled during Q1, Stada pointed to the continuing strength of its underlying Consumer Healthcare portfolio.
As firms in OTC drug, dietary supplement and personal care/beauty sectors reported results for January-March period after Trump announced reciprocal tariffs, they buckled up for more changes in the president’s thinking likely to affect consumer spending as well as their costs.
